Related Experiment Videos
[Chronic interstitial nephritis and mesalazine: 3 new cases?]
M Brouillard1, J D Gheerbrant, Y Gheysens
1Service de Médecine C, Centre Hospitalier, Arras.
Gastroenterologie Clinique Et Biologique
|November 21, 1998
Summary
Mesalazine, a common treatment for inflammatory bowel disease, can cause serious kidney damage. Monitoring kidney function is crucial for patients with Crohn
Area of Science:
- Nephrology
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis.
- Mesalazine is a widely used medication for managing IBD.
- Chronic interstitial nephritis is a serious kidney condition.
Observation:
- Three new cases of chronic interstitial nephritis were identified in patients with IBD.
- Two patients had Crohn's disease, and one had ulcerative colitis.
- All patients were undergoing treatment with mesalazine.
Findings:
- Asymptomatic renal disease was detected via elevated serum creatinine levels.
- Renal biopsies confirmed severe chronic interstitial nephritis.
- Mesalazine withdrawal and corticosteroid treatment resulted in partial renal function improvement in two patients.
Implications:
- Mesalazine may cause kidney toxicity, though the mechanism remains unclear.
- Regular renal function monitoring is essential for IBD patients on mesalazine.
- Early detection and intervention can potentially mitigate severe kidney damage.